DEF 14A: TransCode Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

TransCode Therapeutics is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and potentially attract a broader range of investors.

Summary

• TransCode Therapeutics is holding a special meeting of stockholders on April 21, 2025, to vote on two proposals.
• The first proposal is to approve an amendment to the company's charter to allow the Board of Directors to effect a reverse stock split of the common stock at a ratio ranging from 1-for-10 to 1-for-40.
• The exact ratio will be determined by the Board without further stockholder approval.
• The second proposal is to approve the adjournment of the special meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the reverse stock split proposal.
• The Board of Directors recommends voting for both proposals.
• The primary goal of the reverse stock split is to increase the per share market price of the common stock to meet the minimum bid price requirements for continued listing on the Nasdaq Capital Market, which requires a minimum closing bid price of $1.00 per share.
• As of April 2, 2025, the last reported sale price of TransCode's common stock on the Nasdaq Capital Market was $0.5285 per share.
• The company believes that a higher stock price could also make the stock more attractive to a broader range of investors and potentially increase liquidity.
• If the reverse stock split is approved and implemented, the number of outstanding shares of common stock will be reduced, but each stockholder's percentage ownership will remain approximately the same, except for adjustments due to fractional shares.
• The company will not issue fractional shares; instead, stockholders will have their fractional shares rounded up to the nearest whole number.
• The total number of authorized shares of capital stock will remain at 300,000,000, consisting of 290,000,000 shares of common stock and 10,000,000 shares of preferred stock.
• If the reverse stock split is not approved, the company could be delisted from Nasdaq, which could limit its ability to raise additional equity capital and may lead to a restructuring of liabilities, potentially resulting in a total loss of investment for stockholders.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split and its potential consequences. While the company expresses hope for a positive outcome, it also acknowledges the risks involved.

Positives

• The reverse stock split aims to maintain the company's listing on the Nasdaq Capital Market.
• A higher stock price could attract a broader range of investors, including institutional investors.
• Increased investor interest could lead to greater liquidity for the company's stock.
• Avoiding delisting would preserve the company's ability to raise additional equity capital.
• The Board has the flexibility to determine the exact reverse stock split ratio within the approved range, allowing them to react to market conditions.

Negatives

• The reverse stock split may not increase the stock price over the long term.
• The reverse stock split could decrease the liquidity of the common stock.
• Some stockholders may end up owning odd lots, which can be more difficult to sell.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.
• If the company fails to maintain compliance with Nasdaq's continued listing requirements, its common stock could be delisted.

Risks

• The reverse stock split may not be effective in increasing the stock price or maintaining Nasdaq listing.
• Delisting from Nasdaq could significantly limit the company's ability to raise capital.
• The company may need to seek an in-court or out-of-court restructuring of its liabilities.
• Stockholders could suffer a total loss of their investment in the event of restructuring activities.
• The company is subject to a Discretionary Panel Monitor through December 24, 2025, and could face delisting if it fails to comply with Nasdaq listing rules during this period.

Future Outlook

The company aims to regain and maintain compliance with Nasdaq listing requirements through the reverse stock split, but there is no guarantee of success. The Board has the discretion to implement the reverse stock split or abandon it altogether.

Management Comments

• The Board of Directors recommends a vote FOR the approval of the reverse stock split and the adjournment proposal.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in the biotechnology or pharmaceutical industries facing similar challenges may consider this approach.

Comparison to Industry Standards

• Many companies facing potential delisting from Nasdaq due to failing to meet the minimum bid price requirement have implemented reverse stock splits.
• For example, companies like BioPharmX, and Citius Pharmaceuticals have used reverse stock splits to regain compliance.
• The success of a reverse stock split depends on various factors, including the company's underlying financial performance and market conditions, and there is no guarantee that it will lead to a sustained increase in the stock price.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own, but their percentage ownership should remain approximately the same (except for fractional shares).
• Employees may be affected by the company's ability to maintain its Nasdaq listing and raise capital.
• Customers and suppliers may be impacted by the company's financial stability and ability to operate effectively.
• Creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• Stockholders will vote on the reverse stock split proposal and the adjournment proposal at the Special Meeting on April 21, 2025.
• The Board of Directors will determine the exact reverse stock split ratio, if approved.
• The company will file a certificate of amendment to its charter with the Secretary of State of Delaware if the reverse stock split is approved and the Board decides to implement it.
• The company will announce the determination of the reverse stock split ratio, if implemented.

Key Dates

Keywords

reverse stock split, Nasdaq, listing, common stock, delisting, stockholders, proxy, compliance, capital, TransCode Therapeutics